News
-
-
PRESS RELEASE
Norgine announces European Commission Marketing Authorisation for XOLREMDI® (mavorixafor), the first authorised treatment for patients with WHIM syndrome in the European Union
Norgine receives EC authorization for XOLREMDI® for WHIM syndrome, the first treatment in the EU for this rare condition. Approval based on positive CHMP opinion and Phase 3 trial results -
-
PRESS RELEASE
Norgine announces £23 million new investment as part of more than £50 million committed to expanding medicines manufacturing in Wales
Norgine invests £23 million in expanding medicines manufacturing in Wales, supported by UK Government funding. Expansion strengthens supply capabilities, quality control, and creates new jobs
